Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.80 |
| ▸ | RAB9A | P51151 | 5/20 | 0.80 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | CASP3 | P42574 | 1/20 | 0.70 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032429 | 0.90 | HCAR2 (0.81) | NPC1RAB9AHCAR2KMT2AMEN1 | |
| SCHEMBL8943790 | 0.88 | HCAR2 (0.79) | NPC1RAB9AHCAR2KMT2AMEN1 | |
| SCHEMBL5696427 | 0.87 | HCAR2 (0.78) | NPC1RAB9AHCAR2KMT2AMEN1 | |
| SCHEMBL4293558 | 0.86 | ALDH1A1 (0.80) | NPC1RAB9AHCAR2KMT2AL3MBTL1 | |
| SCHEMBL8689313 | 0.86 | TRPM4 (0.69) | NPC1RAB9AHCAR2KMT2AMEN1 | |
| SCHEMBL4915695 | 0.86 | HCAR2 (0.76) | NPC1RAB9AHCAR2KMT2AMEN1 | |
| SCHEMBL8689332 | 0.86 | HCAR2 (1.00) | NPC1RAB9AHCAR2KMT2AMEN1 | |
| SCHEMBL4914608 | 0.86 | HCAR2 (0.76) | NPC1RAB9AHCAR2KMT2AMEN1 | |
| SCHEMBL18510324 | 0.86 | NPC1 (0.80) | NPC1RAB9AHCAR2KMT2AMEN1 | |
| SCHEMBL5696430 | 0.85 | HCAR2 (0.74) | NPC1RAB9AHCAR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | claimed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | claimed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | claimed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | claimed |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | disclosed |
| US-5741926-A | ANTIDIABETIC AGENT | SHAMAN PHARMACEUTICALS, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1997030019-A1 | ANILINE DERIVATIVES HAVING ANTIHYPERGLYCEMIC ACTIVITY | SHAMAN PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | HCCS, ALAD, HAVCR2 | NPC1 1608/4885RAB9A 2260/4885HCAR2 103/4885 |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | HCCS, ALAD, HAVCR2 | NPC1 1608/4885RAB9A 2260/4885HCAR2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.